ALPACAR (zerlasiran phase 2)

178 patients with stable ASCVD and Lp(a) of 125 nmol/L or more (median 213) at 26 sites in Europe and South Africa: zerlasiran 450 mg every 24 weeks, 300 mg every 16 weeks or 300 mg every 24 weeks lowered time-averaged Lp(a) to week 36 by 85.6, 82.8 and 81.3 percent, with median week-36 reductions of 90 to 96 percent and only mild injection-site reactions. Silence Therapeutics has said it will start the phase 3 outcomes trial only with a partner.